|

Scientific Summits Meeting Live webinar

5 June 2020 – 15h30 to 19h

Expired

This course is expired

Scientific Summits

Chapters

  • 1
    Introduction
  • 2
    Poll: For the Urologists, select the correct answer:
  • 1
    The sense and non-sense of retzius-sparing ralp
  • 2
    Poll: For the urologists, select the correct answer
  • 3
    Discussion: The sense and non-sense of retzius-sparing ralp
  • 4
    Poll: In patients with high-risk PCa
  • 5
    Updated results of high-dose rate brachytherapy in high-risk prostate cancer
  • 6
    Poll: In patients with high-risk PCa (2)
  • 7
    Discussion: updated results of high-dose rate brachytherapy in high-risk prostate cancer
  • 8
    Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned!
  • 9
    Postoperative radiotherapy after prostatectomy: is early salvage rt the new standard? what should we learn from radicals?
  • 10
    Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned! - after
  • 11
    Discussion: postoperative radiotherapy after prostatectomy: is early salvage RT the new standard? What should we learn from radicals?
  • 12
    Poll: For the urologists attending this virtual scientific summits, have you ever performed a radical prostatectomy in M1 PCa?
  • 13
    The place of surgery in MHSPC
  • 14
    Discussion: The place of surgery in MHSPC
  • 15
    Poll: If we perform germline and/or somatic testing in metastatic prostate cancer. how common are BRCA+ (or BRCA like) mutations found?
  • 16
    Poll: In which patients do we expect the best response to PARP inhibitors?
  • 17
    Development and clinical implementation of PARP-inhibitors in PCA management
  • 18
    Discussion: Development and clinical implementation of PARP-inhibitors in PCA management
  • 1
    Introduction
  • 2
    Poll: A nephrectomy as cytoreductive treatment in M+ patients
  • 3
    Time to abandon all cytoreductive nephrectomies?
  • 4
    Discussion: Time to abandon all cytoreductive nephrectomies?
  • 5
    The changing first line treatment paradigm in metastatic clear cell renal cell cancer
  • 6
    Poll: A nephrectomy as cytoreductive treatment in M+ patients - after
  • 1
    Introduction
  • 2
    The expanding role of rt in all stages of urothelial cancer
  • 3
    Poll: Regarding trimodality bladder preserving therapy (TMT) as primary therapy in MIBC, which of the following conditions is a contra-indication?
  • 4
    Poll: Compared to adjuvant chemotherapy alone, current best evidence shows that adding adjuvant radiotherapy improves:
  • 5
    Discussion: The expanding role of rt in all stages of urothelial cancer
  • 6
    Poll: Choose 1 answer
  • 7
    Ongoing trial in MIBC
  • 8
    Poll: Neo-adjuvant cisplatinum-based combination chemotherapy remains the gold standard in MIBC
  • 9
    Discussion: Ongoing trial in MIBC
  • 10
    Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 11
    Poll: Neo-adjuvant pembrolizumab before radical cystectomy in pure-01 study. which statement is correct
  • 12
    Discussion: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 13
    Discussion 2: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 1
    Wrapup from the chairman

Instructors

Lies Martens

Lies Martens

Journalist and presenter

As a media professional, Lies Martens analyzes the errors companies make when they communicate with the press in a crisis. She is an expert, coach and trainer in crisis communication, media and presentation skills. Through many years of experience as a journalist, she is also able to lead a debate and to ask the right questions as an interviewer.

Dr. Christophe Assenmacher

Dr. Christophe Assenmacher

Urologist and robotic surgery
Cliniques de l'Europe

 

 

Prof. Dr. Alberto Bossi

Prof. Dr. Alberto Bossi

Head of the Urology and Prostate Brachytherapy Unit
Gustave Roussy Cancer Institute

 

 

Prof. Dr. Cesare Cozzarini

Prof. Dr. Cesare Cozzarini

Radiation Oncologist
San Raffaele H Scientific Institute

 

 

Prof. Dr. Prasanna Sooriakumaran

Prof. Dr. Prasanna Sooriakumaran

BMedSci(Hons) BMBS(Hons) MRCS PhD PGCMedLaw ADCCLinInv FRCSUrol FEBU USMLE Consultant Urological Surgeon
University College London Hospital

 

 

Prof. Dr. Joaquin Mateo

Prof. Dr. Joaquin Mateo

Physician-scientist & Medical Oncologist
Vall d’Hebron Institute of Oncology

 

 

Prof. Dr. Maarten Albersen

Prof. Dr. Maarten Albersen

UZ Leuven

Prof. Dr. Axel Bex

Prof. Dr. Axel Bex

Clinical Lead of the Specialist Centre for Kidney Cancer and Honorary Associate Professor at UCL Division of Surgical and Interventional Science.
Royal Free Hospital London

 

 

Prof. Dr. Valérie Fonteyne

Prof. Dr. Valérie Fonteyne

Head of Clinics radiotherapy
UZ Ghent

 

 

Prof. Dr. Tom Powles

Prof. Dr. Tom Powles

MBBS, MRCP, MD. Professor of Genitourinary Oncology, Director, Lead for Solid Tumour Research.
Barts Cancer Centre

 

 

Prof. Dr. Alberto Briganti

Prof. Dr. Alberto Briganti

Associate Professor of Urology & Deputy director of the Urological Research Institute (URI)
Università Vita-Salute San Raffaele & IRCCS Ospedale San Raffaele

 

 

Chapters

  • 1
    Introduction
  • 2
    Poll: For the Urologists, select the correct answer:
  • 1
    The sense and non-sense of retzius-sparing ralp
  • 2
    Poll: For the urologists, select the correct answer
  • 3
    Discussion: The sense and non-sense of retzius-sparing ralp
  • 4
    Poll: In patients with high-risk PCa
  • 5
    Updated results of high-dose rate brachytherapy in high-risk prostate cancer
  • 6
    Poll: In patients with high-risk PCa (2)
  • 7
    Discussion: updated results of high-dose rate brachytherapy in high-risk prostate cancer
  • 8
    Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned!
  • 9
    Postoperative radiotherapy after prostatectomy: is early salvage rt the new standard? what should we learn from radicals?
  • 10
    Poll: Adjuvant radiotherapy after prostatectomy should be completely abandoned! - after
  • 11
    Discussion: postoperative radiotherapy after prostatectomy: is early salvage RT the new standard? What should we learn from radicals?
  • 12
    Poll: For the urologists attending this virtual scientific summits, have you ever performed a radical prostatectomy in M1 PCa?
  • 13
    The place of surgery in MHSPC
  • 14
    Discussion: The place of surgery in MHSPC
  • 15
    Poll: If we perform germline and/or somatic testing in metastatic prostate cancer. how common are BRCA+ (or BRCA like) mutations found?
  • 16
    Poll: In which patients do we expect the best response to PARP inhibitors?
  • 17
    Development and clinical implementation of PARP-inhibitors in PCA management
  • 18
    Discussion: Development and clinical implementation of PARP-inhibitors in PCA management
  • 1
    Introduction
  • 2
    Poll: A nephrectomy as cytoreductive treatment in M+ patients
  • 3
    Time to abandon all cytoreductive nephrectomies?
  • 4
    Discussion: Time to abandon all cytoreductive nephrectomies?
  • 5
    The changing first line treatment paradigm in metastatic clear cell renal cell cancer
  • 6
    Poll: A nephrectomy as cytoreductive treatment in M+ patients - after
  • 1
    Introduction
  • 2
    The expanding role of rt in all stages of urothelial cancer
  • 3
    Poll: Regarding trimodality bladder preserving therapy (TMT) as primary therapy in MIBC, which of the following conditions is a contra-indication?
  • 4
    Poll: Compared to adjuvant chemotherapy alone, current best evidence shows that adding adjuvant radiotherapy improves:
  • 5
    Discussion: The expanding role of rt in all stages of urothelial cancer
  • 6
    Poll: Choose 1 answer
  • 7
    Ongoing trial in MIBC
  • 8
    Poll: Neo-adjuvant cisplatinum-based combination chemotherapy remains the gold standard in MIBC
  • 9
    Discussion: Ongoing trial in MIBC
  • 10
    Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 11
    Poll: Neo-adjuvant pembrolizumab before radical cystectomy in pure-01 study. which statement is correct
  • 12
    Discussion: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 13
    Discussion 2: Surgical implications of neo-adjuvant treatment of urothelial cancer (pending)
  • 1
    Wrapup from the chairman